Rising Healthcare Costs Impact Employer Coverage
US employers are adjusting their employee benefit plans in response to a projected 9.2% increase in healthcare costs for 2027. This fiscal pressure is forcing many companies to revisit the inclusion of high-cost treatments, specifically GLP-1 medications commonly prescribed for weight management. Data from the Business Group on Health indicates that 14% of employers have already removed these drugs from their health plans or intend to do so by 2027.
Financial strain is now a primary driver for these corporate policy shifts. Pharmacy expenses, which currently account for 25% of overall healthcare spending for most employers, are expected to rise by 12% next year. Many firms are struggling to balance the demand for modern weight-loss treatments with the reality of increasing insurance premiums.
The Shift in Medication Access
Usage data confirms why these changes are occurring. Two-thirds of employers report higher utilization of GLP-1 drugs among their workforce. This widespread uptake, while potentially beneficial for individual health outcomes, has created significant budgetary hurdles for HR and benefits departments. The share of employers offering coverage for weight-loss medications dropped from 72% in 2025 to 60% in 2026.
Ellen Kelsay, president of the Business Group on Health, described this move as an unfortunate outcome for companies attempting to manage budgets. Still, she noted that the situation serves as a catalyst for a more disruptive approach to how employers deliver value and measure long-term health outcomes. Employers remain committed to sponsoring coverage, but the current cost structure is proving unsustainable for many organizations.
Future Strategies for Employee Health
The broader picture involves a fundamental rethinking of how employers manage health benefits. Organizations are now forced to weigh the efficacy of expensive treatments against the need for fiscal health. Leaders are encouraged to engage their workforces in direct conversations about the necessity for change that eliminates waste and prioritizes high-value medical care.
Accountability for vendor partners has become a central focus. Going forward, firms that successfully manage their healthcare spending will likely reward providers who can prove clinical results. Whether these shifts lead to better long-term health outcomes remains to be seen. Industry observers should watch for how mid-sized companies navigate these cost-containment measures in the coming calendar year, as smaller firms often follow the lead set by major corporations regarding plan designs.